Clarion Hotel Sign Floorplan
This meeting took place in 2018
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Precision Medicine in Cancer (E1)
Organizer(s) Richard Rosenquist, Elaine Mardis and Charles M. Perou
May 6—10, 2018
Clarion Hotel Sign • Stockholm, Sweden
Discounted Abstract Deadline: Jan 9, 2018
Abstract Deadline: Feb 6, 2018
Scholarship Deadline: Jan 9, 2018
Discounted Registration Deadline: Mar 6, 2018
Organized in collaboration with Knut and Alice Wallenberg Foundation
and Science for Life Laboratory
Sponsored by Cancer Research UK, Celgene Corporation, ImmunoGen, Inc. and Thermo Fisher Scientific Inc.
and Science for Life Laboratory
Sponsored by Cancer Research UK, Celgene Corporation, ImmunoGen, Inc. and Thermo Fisher Scientific Inc.
Summary of Meeting:
Thanks to next-generation sequencing, we have started to unravel the genomic landscape that contributes to the pathogenesis and/or evolution of several major cancer entities. For the majority of cancer subtypes, a quite diverse and complex mutation pattern is observed, with a limited number of frequently mutated genes accompanied by a long tail of genes with low-frequency mutations. Some of these genes have already been implied to have diagnostic, prognostic/predictive and even therapeutic impact, while most mutations still require functional validation. In parallel, large efforts have been made to design novel strategies targeting key cellular pathways and processes, which in turn has led to introduction of targeted therapy in selected entities. However, there is still a gap-of-knowledge and urgent medical need to determine how to combine the genetic information with risk-stratification and treatment algorithms in the individual patient, i.e., precision medicine. This symposium will highlight large-scale sequencing efforts carried out in different cancer types, including both solid tumors and hematological malignancies, which have paved the way for the incorporation of next-generation sequencing-based approaches into routine clinical diagnostics and every-day patient care. The conference will encompass the rapidly evolving field of disease monitoring by ultra-sensitive sequencing of tumor-specific mutations, as well as introduce novel approaches and other omics technologies and functional studies that will aid future efforts in precision medicine. Finally, successful examples of how genomic findings have spurred development of targeted therapies will be presented. In summary, the symposium will bring together basic scientists, translational researchers and clinicians to meet and discuss concerted action toward precision medicine in cancer.
View Scholarships/Awards
Thanks to next-generation sequencing, we have started to unravel the genomic landscape that contributes to the pathogenesis and/or evolution of several major cancer entities. For the majority of cancer subtypes, a quite diverse and complex mutation pattern is observed, with a limited number of frequently mutated genes accompanied by a long tail of genes with low-frequency mutations. Some of these genes have already been implied to have diagnostic, prognostic/predictive and even therapeutic impact, while most mutations still require functional validation. In parallel, large efforts have been made to design novel strategies targeting key cellular pathways and processes, which in turn has led to introduction of targeted therapy in selected entities. However, there is still a gap-of-knowledge and urgent medical need to determine how to combine the genetic information with risk-stratification and treatment algorithms in the individual patient, i.e., precision medicine. This symposium will highlight large-scale sequencing efforts carried out in different cancer types, including both solid tumors and hematological malignancies, which have paved the way for the incorporation of next-generation sequencing-based approaches into routine clinical diagnostics and every-day patient care. The conference will encompass the rapidly evolving field of disease monitoring by ultra-sensitive sequencing of tumor-specific mutations, as well as introduce novel approaches and other omics technologies and functional studies that will aid future efforts in precision medicine. Finally, successful examples of how genomic findings have spurred development of targeted therapies will be presented. In summary, the symposium will bring together basic scientists, translational researchers and clinicians to meet and discuss concerted action toward precision medicine in cancer.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, May 6 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, May 10 with a closing plenary session from 17:00 to 19:15, followed by a social hour and entertainment. We recommend return travel on Friday, May 11 in order to fully experience the meeting.
SUNDAY, MAY 6
MONDAY, MAY 7
TUESDAY, MAY 8
WEDNESDAY, MAY 9
THURSDAY, MAY 10
FRIDAY, MAY 11
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, May 6 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, May 10 with a closing plenary session from 17:00 to 19:15, followed by a social hour and entertainment. We recommend return travel on Friday, May 11 in order to fully experience the meeting.
SUNDAY, MAY 6
08:30—09:30
Welcome and Keynote Address
*
Richard Rosenquist,
Karolinska Institutet, Sweden
Session Chair
Session Chair
*
Elaine R. Mardis,
Nationwide Children's Hospital, USA
Session Chair
Session Chair
*
Charles M. Perou,
University of North Carolina at Chapel Hill, USA
Charting the Cancer Genome Landscape: Lessons, Opportunities and Challenges
Charting the Cancer Genome Landscape: Lessons, Opportunities and Challenges
09:30—12:15
Clinical Genomics in Solid Tumors
*
Elaine R. Mardis,
Nationwide Children's Hospital, USA
Session Chair
Session Chair
Serena Nik-Zainal,
University of Cambridge, UK
Landscape of Somatic Mutations in Breast Cancer: Clinical Implications
Landscape of Somatic Mutations in Breast Cancer: Clinical Implications
Coffee Break
Dan Robinson,
University of Michigan, USA
Integrative Clinical Genomics of Advanced Cancer
Integrative Clinical Genomics of Advanced Cancer
Charles Swanton,
Francis Crick Institute, UK
Cancer Evolution and Immune Escape: TRACERx
Cancer Evolution and Immune Escape: TRACERx
14:30—16:30
Workshop 1: Deciphering Cancer by Next-Generation Sequencing
*
Lillian L. Siu,
Princess Margaret Hospital, Canada
Session Chair
Session Chair
Emelie Berglund,
KTH-Royal Institute of Technology, Sweden
Spatial Transcriptomics Analysis of Castration-Resistant Prostate Cancer
Spatial Transcriptomics Analysis of Castration-Resistant Prostate Cancer
Mark A. Rubin,
University of Bern, Switzerland
Swiss Oncology and Cancer Immunology Breakthrough Platform (SOCIBP) for Precision Oncology
Swiss Oncology and Cancer Immunology Breakthrough Platform (SOCIBP) for Precision Oncology
Katie Campbell,
University of California, Los Angeles, USA
Comprehensive Genomics Elucidate Class I-Specific Responses due to Pembrolizumab in Treatment-Naive HNSCC
Comprehensive Genomics Elucidate Class I-Specific Responses due to Pembrolizumab in Treatment-Naive HNSCC
Bojan Losic,
Icahn School of Medicine at Sinai, USA
Immuno-Genomic View of Intra-Tumoral Heterogeneity in Liver Cancer
Immuno-Genomic View of Intra-Tumoral Heterogeneity in Liver Cancer
Alex J. Gooding,
Case Western Reserve University, USA
Novel lncRNA BORG Predicts for Metastatic Relapse and Chemoresistance in Triple-Negative Breast Cancer
Novel lncRNA BORG Predicts for Metastatic Relapse and Chemoresistance in Triple-Negative Breast Cancer
Christian Brueffer,
Lund University, Sweden
RNA-seq-Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers in the Population-Based Multicenter SCAN-B Study
RNA-seq-Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers in the Population-Based Multicenter SCAN-B Study
Noam Auslander,
Wistar Institute Cancer Center, USA
Robust Prediction of Therapeutic Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma
Robust Prediction of Therapeutic Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma
17:00—19:00
Precision Diagnostics in Solid Tumors
*
Charles M. Perou,
University of North Carolina at Chapel Hill, USA
Session Chair
Session Chair
Michael F. Berger,
Memorial Sloan Kettering Cancer Center, USA
Integrated Genomic Assays for Precision Cancer Diagnostics
Integrated Genomic Assays for Precision Cancer Diagnostics
Lillian L. Siu,
Princess Margaret Hospital, Canada
A Decade of Precision Medicine: Reality or Myth?
A Decade of Precision Medicine: Reality or Myth?
Matthew J. Ellis,
Baylor College of Medicine, USA
Integrated Proteogenomics for Biomarker Discovery in Breast Cancer
Integrated Proteogenomics for Biomarker Discovery in Breast Cancer
08:30—09:30
Keynote Address
*
Richard Rosenquist,
Karolinska Institutet, Sweden
Session Chair
Session Chair
Elaine R. Mardis,
Nationwide Children's Hospital, USA
Clinical Cancer Genomics in the Diagnosis of Pediatric CNS Tumors
Clinical Cancer Genomics in the Diagnosis of Pediatric CNS Tumors
09:30—12:15
Clinical Genomics in Hematological Malignancies
*
Catherine J. Wu,
Dana-Farber Cancer Institute, USA
Session Chair
Session Chair
Charles G. Mullighan,
St. Jude Children's Research Hospital, USA
Advances in Genetics and Therapy in Pediatric Acute Lymphoblastic Leukemia
Advances in Genetics and Therapy in Pediatric Acute Lymphoblastic Leukemia
Coffee Break
Richard Rosenquist,
Karolinska Institutet, Sweden
The Molecular Landscape of Chronic Lymphocytic Leukemia: Prognostic and Therapeutic Implications
The Molecular Landscape of Chronic Lymphocytic Leukemia: Prognostic and Therapeutic Implications
Riccardo Dalla-Favera,
Columbia University, USA
Genomics of Diffuse Large B Cell Lymphoma
Genomics of Diffuse Large B Cell Lymphoma
Elli Papaemmanuil,
Memorial Sloan Kettering Cancer Center, USA
Genomic Drivers and Prognosis in Acute Myeloid Leukemia
Genomic Drivers and Prognosis in Acute Myeloid Leukemia
14:30—16:30
Workshop 2: Circulating Cell-Free Nucleic Acid Sequencing and Detection of Minimal Residual Disease
*
Elli Papaemmanuil,
Memorial Sloan Kettering Cancer Center, USA
Session Chair
Session Chair
Adrian V. Lee,
University of Pittsburgh, USA
Targeted Mutation Detection from Fingerstick Capillary Blood using a Breast Cancer-Specific Panel MammaSeq
Targeted Mutation Detection from Fingerstick Capillary Blood using a Breast Cancer-Specific Panel MammaSeq
Celine Everaert,
Ghent University, Belgium
Pan-Cancer Identification of Noncoding RNAs with Biomarker Potential in Plasma
Pan-Cancer Identification of Noncoding RNAs with Biomarker Potential in Plasma
Laura W. Dillon,
NHLBI, National Institutes of Health, USA
Targeted RNA-Sequencing for the Quantification of Measurable Residual Disease in Acute Myeloid Leukemia
Targeted RNA-Sequencing for the Quantification of Measurable Residual Disease in Acute Myeloid Leukemia
Louise Pettersson,
Lund University, Sweden
Monitoring Leukemic Mutations Using Ultrasensitive IBSAFE Digital Droplet Analysis Predicts Relapse of Acute Myeloid Leukemia
Monitoring Leukemic Mutations Using Ultrasensitive IBSAFE Digital Droplet Analysis Predicts Relapse of Acute Myeloid Leukemia
Renate Slind Olsen,
County Hospital Ryhov, Sweden
Circulating Inflammatory Factors Associated with Worse Long-Term Prognosis in Colorectal Cancer
Circulating Inflammatory Factors Associated with Worse Long-Term Prognosis in Colorectal Cancer
Jennifer C. Jones,
NCI, National Institutes of Health, USA
Development of an Exosome Analysis Pipeline for Precision Oncology
Development of an Exosome Analysis Pipeline for Precision Oncology
Johan Lindberg,
Karolinska Institutet, Sweden
Cell-Free DNA Profiling of Metastatic Prostate Cancer Reveals Microsatellite Instability, Structural Rearrangements and Clonal Hematopoiesis
Cell-Free DNA Profiling of Metastatic Prostate Cancer Reveals Microsatellite Instability, Structural Rearrangements and Clonal Hematopoiesis
17:00—19:00
Precision Diagnostics in Hematological Malignancies
*
Richard Rosenquist,
Karolinska Institutet, Sweden
Session Chair
Session Chair
Maria Luisa Sulis,
Columbia University Medical Center, USA
Clinical Implementation of Sequencing in Pediatric Hematology-Oncology Practice
Clinical Implementation of Sequencing in Pediatric Hematology-Oncology Practice
Yanara Marincevic-Zuniga,
Uppsala University, Sweden
Short Talk: DNA Methylation Classification Combined with RNA-Sequencing for Subtype Discovery in Pediatric Acute Lymphoblastic Leukemia
Short Talk: DNA Methylation Classification Combined with RNA-Sequencing for Subtype Discovery in Pediatric Acute Lymphoblastic Leukemia
Mei Wang,
Karolinska Institutet, China
Short Talk: RNA Sequencing-Based Prognostic Score Outperforms Conventional Prognostic Scores in Acute Myeloid Leukemia (AML)
Short Talk: RNA Sequencing-Based Prognostic Score Outperforms Conventional Prognostic Scores in Acute Myeloid Leukemia (AML)
Sylvain Mareschal,
Karolinska Institutet, Sweden
Short Talk: Next-Generation Karyotyping in Acute Myeloid Leukemia
Short Talk: Next-Generation Karyotyping in Acute Myeloid Leukemia
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:45
Disease Monitoring in Cancer Patients
*
Adrian V. Lee,
University of Pittsburgh, USA
Session Chair
Session Chair
Catherine Alix-Panabières,
University Medical Centre, France
Functional Analyses of CTCs in Cancer Patients
Functional Analyses of CTCs in Cancer Patients
Alberto Bardelli,
University of Torino, Italy
Cancer Evolution as a Therapeutic Target
Cancer Evolution as a Therapeutic Target
Coffee Break
Eva Hellström-Lindberg,
Karolinska Institutet, Sweden
High-Throughput Mutational Screening Improves Risk Stratification in Myelodysplastic Syndromes
High-Throughput Mutational Screening Improves Risk Stratification in Myelodysplastic Syndromes
Catherine J. Wu,
Dana-Farber Cancer Institute, USA
Intraclonal Dynamics in Chronic Lymphocytic Leukemia
Intraclonal Dynamics in Chronic Lymphocytic Leukemia
Suresh K. Alahari,
Louisiana State University Health Sciences Center, USA
Short Talk: Utilization of MicroRNAs in the Era of Personalized Medicine
Short Talk: Utilization of MicroRNAs in the Era of Personalized Medicine
Shumaila Sayyab,
Uppsala University, Sweden
Short Talk: Clonal Evolution of Acute Lymphoblastic Leukemia Cells from Diagnosis to Relapse
Short Talk: Clonal Evolution of Acute Lymphoblastic Leukemia Cells from Diagnosis to Relapse
12:00—14:15
SciLifeLab Lunch Seminar: Cutting-Edge Technologies in Precision Cancer Medicine (Must Register in Advance)
Register here to secure your lunch. There will also be an opportunity to register for the seminar on site at Clarion Hotel Sign, however we will not be able to offer you lunch.
More information about the program and registration: https://www.scilifelab.se/scilifelab-lunch-seminar-cutting-edge-technologies-in-precision-cancer-medicine
More information about the program and registration: https://www.scilifelab.se/scilifelab-lunch-seminar-cutting-edge-technologies-in-precision-cancer-medicine
17:00—19:00
Novel Approaches in Cancer Genomics
*
Matthew J. Ellis,
Baylor College of Medicine, USA
Session Chair
Session Chair
David T. Miyamoto,
Massachusetts General Hospital, USA
Molecular Characterization of Circulating Tumor Cells for Precision Cancer Medicine
Molecular Characterization of Circulating Tumor Cells for Precision Cancer Medicine
Olli Kallioniemi,
Science for Life Laboratory, Sweden
Precision Systems Medicine to Tailor Cancer Treatments
Precision Systems Medicine to Tailor Cancer Treatments
Jeroen Roose,
University of California, San Francisco, USA
Short Talk: Predicting Synthetic Lethality in the Context of PI3 Kinase Inhibition with High Fidelity
Short Talk: Predicting Synthetic Lethality in the Context of PI3 Kinase Inhibition with High Fidelity
Arvind Singh Mer,
University of Toronto, Canada
Short Talk: Systematic Identification of Genomic Predictors for Anticancer Drug Sensitivity in Patient-Derived Xenografts
Short Talk: Systematic Identification of Genomic Predictors for Anticancer Drug Sensitivity in Patient-Derived Xenografts
Päivi Östling,
Science for Life Laboratory, Karolinska Institutet, Sweden
Short Talk: Precision Systems Medicine in Urological Tumors - Molecular Profiling and Functional Testing
Short Talk: Precision Systems Medicine in Urological Tumors - Molecular Profiling and Functional Testing
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:30
Novel Targets, Novel Therapies I
*
Olli Kallioniemi,
Science for Life Laboratory, Sweden
Session Chair
Session Chair
Gerald P. Linette,
University of Pennsylvania, USA
Melanoma Neoantigen Discovery and Clinical Validation
Melanoma Neoantigen Discovery and Clinical Validation
Winette T. Van Der Graaf,
Institute of Cancer Research, UK
Targeting the Kinome in Cancer: The Need for Return Tickets from Bench to Bedside, Exemplified by the Progress in Understanding Gastrointestinal Stromal Tumors (GIST)
Targeting the Kinome in Cancer: The Need for Return Tickets from Bench to Bedside, Exemplified by the Progress in Understanding Gastrointestinal Stromal Tumors (GIST)
Coffee Break
Kenna Rael Mills Shaw,
University of Texas, MD Anderson Cancer Center, USA
Precision Cancer Medicine: Neither Silver Bullet Nor an Illusion
Precision Cancer Medicine: Neither Silver Bullet Nor an Illusion
Thomas Helleday,
Karolinska Institutet, Sweden
Targeting the DNA Damage Response in Cancer
Targeting the DNA Damage Response in Cancer
Ron S. Gejman,
Memorial Sloan Kettering Cancer Center, USA
Short Talk: The Ability of T Cell Antigens to Cause Tumor Cell Rejection Is Dependent on Tumor Cell Subclone Frequency
Short Talk: The Ability of T Cell Antigens to Cause Tumor Cell Rejection Is Dependent on Tumor Cell Subclone Frequency
14:30—16:30
Workshop 3: Identifying Novel Targets and Therapies
*
Laurence Zitvogel,
Institut Gustave Roussy, France
Session Chair
Session Chair
Eva Marina Schmidt,
Ludwig-Maximillians-Universität München, Germany
Therapeutic Targeting of Tumor Heterogeneity by Inhibition of MAPK and NOTCH Signaling in Colorectal Cancer
Therapeutic Targeting of Tumor Heterogeneity by Inhibition of MAPK and NOTCH Signaling in Colorectal Cancer
Alexandre Couture,
Normandy University, France
New Cancer Immunotherapy Strategies Based on the Use of Artificial Antigen-Presenting Cells for Activating Potent Anti-Tumor Specific CD4+ T Lymphocytes
New Cancer Immunotherapy Strategies Based on the Use of Artificial Antigen-Presenting Cells for Activating Potent Anti-Tumor Specific CD4+ T Lymphocytes
Catríona M. Dowling,
Royal College of Surgeons in Ireland, Ireland
Discovery of a Novel Histone Deacetylase 6 Inhibitor that Kills Drug-Resistant Breast Cancer
Discovery of a Novel Histone Deacetylase 6 Inhibitor that Kills Drug-Resistant Breast Cancer
Purusottam Mohapatra,
University of Lund, Sweden
WNT5A-IL-6 Signaling as a Therapeutic Target in Melanoma
WNT5A-IL-6 Signaling as a Therapeutic Target in Melanoma
Arthur L. Shaffer III,
NCI, National Institutes of Health, USA
Ibrutinib Resistance in Diffuse Large B cell Lymphoma: Evolution, Novel Dependencies and Therapeutic Options
Ibrutinib Resistance in Diffuse Large B cell Lymphoma: Evolution, Novel Dependencies and Therapeutic Options
Göran Jönsson,
Lund University, Sweden
Comprehensive Genomic Analysis Predict Clinical Benefit of Adoptive T Cell Therapy in Melanoma
Comprehensive Genomic Analysis Predict Clinical Benefit of Adoptive T Cell Therapy in Melanoma
Yardena Samuels,
Weizmann Institute of Science, Israel
UVB-Induced Genomic Alterations Dictates Anti-Tumor Immune Response against Melanoma
UVB-Induced Genomic Alterations Dictates Anti-Tumor Immune Response against Melanoma
17:00—18:45
Novel Targets, Novel Therapies II
*
Kenna Rael Mills Shaw,
University of Texas, MD Anderson Cancer Center, USA
Session Chair
Session Chair
Renier Brentjens,
Memorial Sloan Kettering Cancer Center, USA
Talk Title to be Announced
Talk Title to be Announced
Eric Tran,
Providence Cancer Institute, USA
Immunogenicity and Immunotherapeutic Targeting of Mutated Neoantigens in Human Cancer
Immunogenicity and Immunotherapeutic Targeting of Mutated Neoantigens in Human Cancer
Laurence Zitvogel,
Institut Gustave Roussy, France
Resistance to Immune-Checkpoint Blockade in Cancer
Resistance to Immune-Checkpoint Blockade in Cancer
18:45—19:15
Closing Remarks
*
Jonas Bergh,
Karolinska Institutet, Sweden
A Clinical Oncologist's Perspective
A Clinical Oncologist's Perspective
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
|
|
We gratefully acknowledge additional support for this conference from:
|
|
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: John Monson,
Director of Corporate Relations, Email: johnm@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
